Search
Pexidartinib
go.drugbank.com/drugs/DB12978ApprovedInvestigationalPexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor … [A182243] Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.[L7901]
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesCRx-119
go.drugbank.com/drugs/DB05688ExperimentalCRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine.
Brilliant green cation
go.drugbank.com/drugs/DB11279ApprovedVet approvedBrilliant green, or ethanaminium, is a derivative of triarylmethane dye that has been used as a dye to color silk and wool. … Due to its inhibitory actions against Gram positive microorganisms, brilliant green can be found in antiseptic products such as solutions and swabs used to prevent infection.
Mixtures: Kerr 100 Triple Dye Dispos-ATozuleristide
go.drugbank.com/drugs/DB15375InvestigationalTozuleristide is under investigation in clinical trial NCT02464332 (Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery).
Prasterone
go.drugbank.com/drugs/DB01708ApprovedInvestigationalNutraceuticalIn November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause … DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter dietary supplements.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: 3β-hydroxyandrost-5-en-17-one, 3-beta-hydroxy-5-androsten-17-oneBenzophenone
go.drugbank.com/drugs/DB01878ApprovedSubstituted benzophenones such as oxybenzone and dioxybenzone are used in sunscreen.
Mixtures: nanocare Moisturizing Sunscreen SPF 50, nanocare Moisturizing Sunscreen SPF 50Topiroxostat
go.drugbank.com/drugs/DB01685InvestigationalRenal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended. … Xanthine oxidase inhibitors are classified into two groups; purine analogs such as [DB00437] and [DB05262], and non-purine agents which includes topiroxostat.
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C8 InhibitorsSynonyms: 4-(5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrilePhenelzine
go.drugbank.com/drugs/DB00780ApprovedInvestigational[A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
Categories: Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2C19 InhibitorsMeningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
go.drugbank.com/drugs/DB10061ApprovedInvestigational[L43518] Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, marketed as MENVEO, was first approved by the FDA in 2010.[L43518] … used to prevent invasive meningococcal disease, which is caused by bacteria _Neisseria meningitidis_ entering the bloodstream and invading the blood-brain barrier to cause a variety of infections such as
Levopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnIt was sold as an antitussive, but it was removed from the market in the 70s.[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. … This drug presented different dosages and it was administered as a capsule or suspension.